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Expression of insulin-like growth factor-i in uremic rats: Growth
hormone resistance and nutritional intake. This study was designed to
test the hypothesis that induction of insulin-like growth factor-i (IGF-i)
is reduced in the uremic rat liver, which would help to explain the
purported growth hormone resistance noted in uremia. IGF-l mRNA,
in the steady state and after acute induction by two doses of 100 jzg/100
g body wt recombinant human growth hormone (rhGH), was quanti-
tated by solution hybridization in total liver RNA, extracted by the
guanidine thiocyanate/cesium chloride gradient method. Eighteen
Sprague-Dawley rats weighing 100 to 102 g were randomly divided into
three groups: sham-operated control rats (control group); 5/6 nephrec-
tomized rats (uremic group); and sham-operated controls with dietary
intake matching that of the uremic rats (pair-fed group). The results
showed that the steady state liver IGF-1 mRNA was 1.7 arbitrary
densitometry units (ADU) in the uremic animals, and was lower than
the value of 3.2 ADU in the control animals (P < 0.05). After the acute
administration of rhGH, the liver IGF-l mRNA of control, uremic and
pair-fed groups showed mean increases of 154% (P < 0.05), 124% (not
significant, NS) and 117% (NS), respectively. The lack of IGF-l
induction in the uremic group supported the concept of growth hormone
resistance in uremia. In addition, a similar lack of induction was
observed in the pair-fed group, whose food intake was 65% that of the
control animals. This indicated that the lack of IGF-l induction was at
least partially due to the reduced food intake. Our data also showed that
the expression of growth hormone receptor mRNA in the uremic group
was decreased to 41% of the control group (P < 0.05), while the
decrease in expression of growth hormone receptor mRNA of the
pair-fed group was 87% of the value in the control group (P = NS). We
conclude that the lack of IGF-l induction by exogenous rhGH in the
pair-fed group was due, in large part, to the reduced food intake. By
contrast, the growth hormone resistance in the uremic group was due to
the combined effects of both reduced food intake and decreased growth
hormone receptor at the transcription level.
Growth failure is a serious complication of children suffering
from chronic renal insufficiency. With recombinant human
growth hormone (rhGH) becoming more readily available, the
use of exogenous rhGH to promote growth is being advocated
as the standard of care in children with chronic renal insuffi-
ciency [1—3]. However, there is no documented evidence of
growth hormone deficiency in children with chronic renal
insufficiency. The growth-promoting effect of therapeutic doses
of rhGH in children with chronic renal insufficiency is being
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advocated as indirect evidence of growth hormone resistance in
chronic uremia. In fact, normal or elevated serum growth
hormone concentrations are commonly reported in uremic
patients [4]. Circulating concentrations of growth hormone and
IGF-l may vary, due to the different degrees of severity of renal
excretory impairment and catabolic capabilities. These con-
founding variables render such parameters less exacting as
indicators to evaluate the growth hormone/IGF axis in uremia,
even though these are the only practical parameters accessible
in patients. The concept of growth hormone "resistance" in
uremia has been proposed as a rationale for the use of pharma-
cological doses of rhGH, although measurable evidence of the
target tissue "resistance" is still lacking.
The growth promoting effect of growth hormone is largely
mediated by insulin-like growth factor-i (IGF-i) [5, 6]. The
steady state expression of IGF-1 is highest in the liver, which is
the major source of circulating IGF-l [7]. The level of steady
state expression of IGF-l is thought to be affected by growth
hormone as suggested by the observations that liver IGF-i is
low in hypophysectomized rats [7] and high in growth hormone
transgenic mice [8]. The growth hormone induction of IGF-l in
different tissues such as liver, muscle, kidney and bone has
been documented [7, 9] in rats as well as in other species such
as pigs [10] and fish [11].
Because the growth promoting effect of growth hormone is
mediated through IGF-i, which is responsible for the rapid
response to exogenous growth hormone administration, the
induction of IGF- 1 mRNA after the acute administration of
exogenous rhGH may serve as a sensitive measurement to
gauge the effect of growth hormone and, therefore, may also
serve as an indicator for the purported growth hormone resis-
tance in chronic uremia. The purpose of this study is to examine
the induction of liver IGF-1 mRNA by exogenous growth
hormone as a direct measure of the presence of growth hor-
mone resistance in this target tissue in the uremic state.
Method
Male Sprague-Dawley rats, with starting body weights of 100
g (Table 1), were subjected to a 2/3 nephrectomy of the left
kidney followed by a contralateral nephrectomy one week later,
resulting in a 5/6 nephrectomized uremic rat model [12]. For the
first stage operation, the animal was anesthetized with ket-
amine, and an opening was made at the left flank. The left
kidney was exposed. Both the upper and lower poles of the
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Table 1. Initial body weight (IBW), body weight gained (BW), total
food intake in three weeks, and serum urea nitrogen (SUN) and
creatinine in control, uremic and pair-fed animals
IBW BW
g
Food
intake SUN
Serum
creatinine
mg/dl
Control 100 1 130 1 596 8 15 2 0.3 0.01
Uremic 101 1 58 ia 367 4° 60 ioa 1,2 0.01
Pair-fed 102 1 53 14° 370 26° 11 2 0.3 0.01
Data are means SEM.
a Significantly different from Control, P < 0.01
kidney were tied off before the poles were excised. Pressure
was applied to the cut ends until bleeding stopped, after which
the incision was closed up. In the second stage of the operation
one week later, the right flank was opened after the animal was
ketamine anesthetized, and the right kidney was tied off and
excised. Control rats were subjected to sham operations. There
were three groups of experimental animals: sham-operated
control rats, uremic rats, and the sham-operated controls pair-
fed to the uremic rats; with N = 6 in each group. The pair-fed
animals provided a group to examine the effect of reduced food
intake on the induction of IGF-l mRNA by exogenous rhGH.
Pair feeding started right after the second stage operation. The
control and uremic rats were fed ad libitum. Standard labora-
tory chow (Prolab R-M-H 3000; Agway, Syracuse, New York,
USA) containing 22.5% crude protein were used. All animals
were housed in a temperature and humidity controlled room
with a 12/12 hours of light/dark cycle. The protocol was
approved by the Animal Use Committee of Virginia Common-
wealth University's Medical College of Virginia.
Three weeks after uremia was produced by the 5/6 nephrec-
tomy operations, the animals were given rhGH at a dose of 100
p.g/l00 g body wt in order to measure the induction of liver
IGF-l mRNA. A total of two doses were given subcutaneously;
the first dose at 6:00 p.m. the day before the animals were killed
and the second dose 12 hours later at 6:00 a.m. The animals
were anesthetized with ketamine before exsanguination four
hours after the second dose. Serum samples were collected for
determination of creatinine and urea nitrogen using a Beckman
Creatinine Analyzer and SMAC 20, respectively, as described
before [121. Liver samples were frozen in liquid nitrogen and
kept at —70°C until extraction of total RNA.
Total RNA was prepared by homogenizing liver samples with
a dounce tissue grinder (Wheaton, Millville, New Jersey, USA)
in 4 M guanidine thiocyanate and 1% sodium dodecyl sulphate
and isolated by centrifugation at 45,000 rpm for 16 hours and
20°C through a 5.7 M cesium chloride cushion [13]. The RNA
pellet was dissolved in DEPC treated water, followed by
precipitation with 2.5 x volume of 100% ethanol in the presence
of 0.3 M NaOAc at —20°C for 18 hours. The precipitate was
redissolved, and an aliquot was used for spectrophotometric
quantification of the samples at O.D. 260/280. The accuracy of
the quantification as well as the integrity of the RNA prepara-
tion was confirmed by running an 8% formaldehyde gel and
comparing the intensity of the 28s and l8s ribosomal bands with
ethidium bromide staining.
The rat IGF- 1 probe (from C. Roberts, Jr. and D. LeRoith of
NIDDK of the National Institutes of Health) was a 376 bp
Hindlll/EcoRl fragment, in riboprobe vector pGEM-3. This
construction was linearized with Hindlll [7]. The growth hor-
mone receptor probe (from W. Baumbach of American Cyan-
amid, Princeton, New Jersey, USA) was a 544 bp HindllllBglll
fragment cloned between the Hindlll and Bamhl sites of
pGEM-3 (Promega, Madison, Wisconsin, USA) [14]. For both
probes, the antisense RNA was synthesized with T7 polymeras
after plasmid linearization with Hindill, as part of the Promega
in vitro transcription kit (Promega) and [alpha-32P] GTP (New
England Nuclear, Boston, Massachusetts, USA). Twenty mi-
crograms of total liver RNA was dried with a speed-vac and
heated with 2 p1 (approximately 200,000 cpm) of labeled an-
tisense IGF- 1 probe in 75% formamide and 400 m NaC1 at
85°C for five minutes before hybridization at 55°C for 16 hours.
After hybridization, 6 jg of RNAase A and 250 units of
RNAase TI (Sigma Chemical Co., St. Louis, Missouri, USA)
were added in 300 ,ul of RNAase buffer and incubated for 45
minutes at 42°C. Then to each tube was added 5 1.d of 10 mglml
of protease K (Sigma) and 10 p1 of 10% SDS. The incubation
was continued at 37°C for another 15 minutes. The protected
fragments were isolated by ethanol precipitation after phenol/
chloroform extraction, and size separated on a 6% polyacryl-
amide/8 M urea denaturing gel [15]. The probe was designed to
give two protected fragments: IGF-la with a size of 224 bp and
IGF- lb with a size of 386 bp. Quantification of the IGF- la band
was performed with a densitometer (Shimadzu CS-9000, Shi-
madzu Corp., Kyoto, Japan), and the results expressed in
arbitrary densitometry units (ADU).
Results
As shown in Table 1, at the start of the experiment, body
weights of all three groups of animals were similar. At the end
of the experimental period, the uremic rats showed a significant
decrease in weight gain as compared to the control rats. The
pair-fed group showed similar diminution of weight gain as the
uremic animals. The food intake of the pair-fed group, similar to
that of the uremic animals, was significantly less than that of the
control (Table 1). The significant increase in both the serum
creatinine and serum urea nitrogen (Table 1) indicated reduced
renal function in the uremic rats. These parameters were
normal in the pair-fed animals, and no different from that of
controls.
When liver total RNA samples were probed for IGF-l
mRNA, the results (Fig. 1) showed that the steady state IGF-1
mRNA was significantly reduced compared to that of the
controls. When growth hormone was administered, the ex-
pected induction was observed in the control rats but not in the
uremic rats. As shown in Figure 2, when these bands were
scanned and the results in mean SEM expressed in ADU. The
IGF-l mRNA in the control rats was 3.2 0.2 ADU. In the
uremic rats, the IGF-l mRNA was 1.7 0.2 ADU, which was
significantly lower than the control rats (P < 0.001). The IGF-l
mRNA of the pair-fed group at 2.4 0.3 ADU fell between the
control and the uremic groups, but the difference was not
significant. With growth hormone administration, the liver
IGF-l mRNA in the control became 154% of that of the steady
state (Fig. 2), which was a significant increase (P < 0.001).
While the IGF-l mRNA in uremic rats was 112% of its baseline
value (Fig. 2); the increase was not significant, indicating a
resistance to growth hormone induction in the uremia state. The
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Control
Pair-fed
Uremic
-GH +GH
Fig. 1. Hepatic total RNA probed for IGF-1,
without growth hormone administration
(—GH) and with growth hormone
administration (+GH). Figure shows three
different samples from each group.
IGF-l mRNA of the pair-fed controls, albeit at 124% over the
baseline steady state value, was not significantly affected by the
acute rhGH administration.
When the abundance of the growth hormone receptor tran-
script was evaluated with a RNAase protection method, the
growth hormone receptor mRNA in the uremic animals (Fig. 3)
was shown to be significantly reduced (0.64 0.14 ADU) as
compared to that of the control animals (1.60 0.25 ADU, P <
0.05). The growth hormone receptor mRNA in the pair-fed
animals (1.40 0.04 ADU) was not statistically different from
that of the control. The exogenous rhGH administration did not
result in a statistically significant increase in any group.
Discussion
The data from this study demonstrated that in uremia, hepatic
IGF-1 induction fails to materialize after a challenge dose of
rhGH administration, while the expected induction was evident
in the control animals. The induction of IGF- 1 following exog-
enously administered growth hormone has been well docu-
mented in normal and hypophysectomized animals and shown
in different tissues, including liver, lung, heart, kidney, and
bone growth plate of rats [7, 9], and in different animal species
such as pig and fish [10, 11], and regardless of the duration of
such administration in terms of weeks [10, 11] or hours [7, 91. A
significant increase in liver and bone growth plate IGF- 1 mRNA
has been shown as early as six hours after the first dose of
growth hormone administration in hypophysectomized rats and
24 hours after administration in normal rats. The lowest effec-
tive dose of growth hormone in these experiments was 100
pg!l0O g body weight [9]. When this dose of growth hormone
was used in our experiment, the control animals showed a
significant increase of liver IGF-1 mRNA. But the same dose of
growth hormone treatment failed to produce a significant in-
crease in the liver IGF-l mRNA in our uremic rats. Because the
failure to respond is also observed in the rats pair-fed to the
uremic rats, the food intake of the uremic rats, averaging 65%
that of the control rats, was apparently responsible, at least
partly, for the lack of induction of liver IGF- 1 mRNA to the
growth hormone challenge. Therefore, the importance of food
intake in the induction of liver IGF- 1 mRNA was well illus-
trated by these data. This reduced response of liver IGF-l
mRNA can be due to the direct effect of decreased nutrient
supply, or indirectly due to increased glucocorticoid as a result
of restriction of food intake [16]. In hepatocytes, a possible role
in protein kinase C in the growth hormone regulation of IGF
mRNA is implicated [17]. Otherwise, little information is avail-
able concerning the signal transduction leading to the induction
of IGF-1.
Our data on the liver IGF-1 mRNA in the three groups of rats
not given rhGH, represented the steady state IGF-1 mRNA in
the control, uremic and the pair-fed animals. The data showed
that liver IGF-1 mRNA was significantly reduced in the uremic
group as compared to that of the control group. The liver IGF-I
mRNA in the pair-fed animals, though lower than the control
animals, was not statistically different. This suggests that the
reduced food intake to 65% of optimal food consumption may
affect induction of liver IGF- 1 by a challenge dose of rhGH, but
had no affect on the steady state expression of liver IGF- 1.
Underwood et al [18, 19] first showed that reduced dietary
nutrients adversely affect serum IGF-l in humans and rats. The
reduction of liver IGF-1 expression by either fasting [20] or a
low protein diet [21] was later confirmed. The effect of fasting
and refeeding, which, respectively, decreased and increased
IGF-l gene expression, was evident within 24 hours of such
maneuvers [22]. Underwood et al [18] demonstrated a correla-
tion between the decrease of serum IGF-1 and negative nitrogen
balance during fasting. Thus, net weight gain in the pair-fed rats
should be predictive of the lack of statistically significant
reduction in liver IGF-1 mRNA as compared to that of the
control rats.
In studies showing that liver IGF- 1 mRNA was decreased by
fasting [20], low protein diet, and experimental diabetes [21], a
OH (—)
OH (—)
01-I (+)
OH (+)
a
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Fig. 3. Liver growth hormone receptor mRNA without (—GH) and
with rhGH (+GH) administration. Symbols are: (U) control; (0)
uremic; () pair-fed. Values are mean SEM in arbitrary densitometry
units (ADU). * Significantly different from control and pair-fed, P <
0.05.
Fig. 2. Hepatic IGF-1 mRNA in control (U, A), uremic (, B) and
pair-fed (0, C) animals without (—GH) and with (+GH) acute rhGH
administration. Values are means SEM in arbitrary densitometry unit(ADU). * Significantly different from control (—OH), P < 0.05.
high correlation was found between the change in mRNA and
circulating IGF- 1 [20, 21]. Serum IGF-1 was not measured in
this study because normal serum IGF-l concentrations have
already been reported in both uremic human and rats [23, 24].
Normal circulating IGF-l could result from renal retention
secondary to reduced renal clearance. In addition, the kidney
being a major clearance site of IGF- 1 [25], with the decreased
renal mass in renal insufficiency, it is reasonable to expect that
the catabolic rate of IGF- 1 is decreased, resulting in an accum-
mulation of the protein, similar to retinol/retinol binding protein
accummulation and decreased catabolism in chronic uremia
[26]. Thus, the uncertain reductions in renal excretion and
variable rates of catabolism render the measurement of serum
IGF-1 concentrations less meaningful as an indicator of the
relationship between IGF- 1 expression and its circulating con-
centrations. Even without such uncertainties in interpreting
serum IGF-1 data, and in view of the fact that no study has
found subnormal serum growth hormone in uremic animals [24]
or humans [23], the decrease in the steady state, liver IGF-l
mRNA, as shown in the uremic animals in this study, can still
be considered a measure of chronic growth hormone resistance
in uremia.
In order to explain the tissue growth hormone resistance
observed in this study, we measured the abundance of the
growth hormone receptor mRNA in liver total RNA in the three
groups of experimental animals. The expression of liver growth
hormone receptor in the uremic group, as compared to the
control group, was significantly reduced but not that of the
pair-fed group. This data indicated that the observed growth
hormone resistance in the pair-fed group was due primarily to
the effect of reduced food intake, affecting post-receptor
events. At 65% optimal food intake, the pair-fed animals in the
present study must have catabolized a portion of the protein to
partially fulfill their caloric need [19]. So even though the
protein content of the diet is 15%, the effective metabolic
consumption of protein in the pair-fed animals was likely much
lower, and may resemble, to some degree, the rats fed a
restricted protein diet [21]. In VandeHaar et al's experiments
[21], rats fed a low (5%) protein diet for up to four weeks
showed a significant slow down in body weight gain accompa-
nied by reduced serum IGF- 1, but no change in liver growth
hormone binding or any effect on the abundance of liver growth
2-
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hormone receptor mRNA, findings which were similar to our
pair-fed group and contrasted with our uremic group.
The data of Finidori, Postel-Vinay and Kleinknecht [271
showed reduced growth hormone binding in the liver of uremic
rats. In the present study, our data suggested that in uremia, the
defect in growth hormone receptor binding is extended to the
transcriptional level. It has been reported that in hypophysec-
tomized rats, the liver growth hormone receptor mRNA was
unaffected even though the growth hormone binding was de-
creased by 50% as compared to intact animals [281. These
findings suggested that the growth hormone receptor function
was controlled by its translation rather than by its transcription
[291. The results from the uremic rats in this study clearly
showed that growth hormone resistance was due partly to
reduced food intake and partly to reduction of growth hormone
receptor mRNA. As for the control of growth hormone receptor
gene expression, the abundance of liver growth hormone recep-
tor mRNA was reduced by fasting and the lack of insulin, but
unaffected by low protein intake [301. It is well recognized that
defective growth hormone receptor can lead to growth hormone
insensitivity as in Laron syndrome [31], so we speculate that
one of the mechanisms of the growth hormone resistance in
uremia may be secondary to decreased growth hormone recep-
tor function.
Finally, our data demonstrating the failure of the induction of
liver IGF- 1 in response to growth hormone challenge is a direct
indication of growth hormone resistance in uremia. It is possi-
ble that in uremia, the growth promoting effect of exogenously
administered rhGH is due to changes of IGF-l mRNA and/or
IGF-1 in tissues other than liver, such as kidney, bone and
muscle, where the paracrine/autocrine action of IGF-1 has
proven to be of critical importance in growth promotion [321. It
is also possible that the effect of exogenous rhGH is exerted on
the IGF-l binding proteins [33, 34], which are likely to exert
profound effects on the availability and function of IGF-l.
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